Novus International, a global leader in health and nutrition solutions for the animal agricultural industry, is seeking novel opportunities and ideas in the area of inhibition of methanogenesis in ruminants (cows, sheep etc.), with a goal of minimising anthropogenic methane emissions that arise from livestock. The team is interested in novel opportunities that have potential to become commercial products, with high in vivo efficacy and safety, and a competitive manufacturing cost. Approaches of Interest: <ul> <li>There is a particular interest in novel approaches...</li></ul>

Novus International is seeking novel opportunities and ideas in the area of inhibition of methanogenesis in ruminants (cows, sheep etc.), with a goal of minimising anthropogenic methane emissions that arise from livestock. 


Practical Solutions for Methanogenesis Inhibition in Ruminants

Daiichi Sankyo, a global pharmaceutical company, is seeking novel in vivo models to understand pathological mechanisms in human disease. Indications of interest include microcirculatory disorders (e.g. INOCA, type II myocardial infarction, coronary microvascular dysfunction, etc.), dry aged-macular diseases, psychiatric diseases (neuroinflammatory related model for &#x201C;CIAS of schizophrenia&#x201D; and / or &#x201C;MDD&#x201D;) and neurodegenerative diseases. <h3>Approaches of Interest:</h3> <ul> <li>Mouse models are of interest for all indications</li> <li>Rabbit, pig or other large animal models are of...</li></ul>

Daiichi Sankyo, a global pharmaceutical company, is seeking novel in vivo models to understand pathological mechanisms in human disease.

Seeking Novel in vivo Models to Understand Pathological Mechanisms in Human Disease

Daiichi Sankyo, a global pharmaceutical company, is seeking opportunities to collaborate with institutes seeking protease inhibitors for disease treatment. Daiichi Sankyo has in&#x2011;house technology to make specific protease inhibitors and would ideally like to work with researchers who have identified proteases involved in mediating diseases, but who have not yet developed an inhibitor for the target protease. <h3>Approaches of Interest:</h3> <ul> <li>All disease areas that do not currently have protease inhibitor treatment are of interest</li> <li>There is a particular interest in...</li></ul>

Daiichi Sankyo, a global pharmaceutical company, is seeking opportunities to collaborate with institutes seeking protease inhibitors for disease treatment

Developing Extracellular Protease Inhibitors for Disease Treatment

Johnson &amp; Johnson Innovation is seeking novel therapeutic approaches to inhibit type 2 inflammation. Approaches which have a systemic effect on type 2 inflammation in relevant diseases (e.g., atopic dermatitis, asthma, eosinophilic esophagitis) are of interest. Novel oral therapeutic strategies targeting the Th2 signalling pathway are of particular interest (e.g., small molecule inhibitors of STAT6, IL-4R etc.). Approaches targeting other relevant pathways are also of interest if they provide a systemic approach with transformational therapeutic potential...

Johnson & Johnson Innovation is seeking novel therapeutic approaches to inhibit type 2 inflammation in atopic dermatitis, asthma and eosinophilic esophagitis.

Novel Therapeutic Approaches to Inhibit Type 2 Inflammation

A global fortune 500 company is seeking research and technologies related to the treatment or prevention of chronic inflammatory skin conditions (e.g. atopic and allergic dermatitis). Research should relate to therapeutic or preventative interventions to modulate disease severity/ progression. The intervention should achieve an extended duration of efficacy with a single/ short administration window. Treatments should reduce inflammation or pruritus for at least 6 months. Our client is particularly interested in validated research ready for further development...

A global fortune 500 company is seeking research and technologies related to the treatment or prevention of chronic inflammatory skin conditions.

Novel Approaches to Treat and/or Prevent Progression of Chronic Inflammatory Skin Conditions With a Long Duration of Efficacy

A multinational pharmaceutical company is seeking novel biology or therapeutic compounds for the treatment of Immunology &amp; Inflammation (I&amp;I) diseases, such as asthma and chronic obstructive pulmonary disorder (COPD). The team is particularly interested in approaches that have a novel mechanism of action for these diseases with no therapeutics currently in the clinic acting on the same target, however differentiated modalities for known targets are also of interest (e.g. small molecule or oral peptides for validated targets with biologics). <h3>Approaches of...</h3>

A multinational pharmaceutical company is seeking novel targets and therapeutics for immunology and inflammation diseases.

Novel Biology or Therapeutic Compounds for Treatment of Immunology & Inflammation Diseases

A top five pharmaceutical company wishes to identify protein engineering research and technologies that support the development of therapeutics with bi/multi-specific conditional activity. Our client is particularly interested in technologies which achieve conditional activation (e.g., by one of the approaches outlined below) which can be applied across multiple therapeutics and clinical indications. Approaches of Interest: <ul> <li>Activation by specific pH, proteases, small molecule binding or ligand binding</li> <li>Structural occlusion mechanisms i.e. engagement of a...</li></ul>

A top five pharmaceutical company  wishes to identify protein engineering technologies that support the development of therapeutics with bi/multi-specific conditional activity.

Seeking Protein Engineering Approaches for Conditionally-activated Therapeutics

BicycleTx Ltd. (Bicycle&#xAE;) has developed an extensive library of small molecule compounds called &#x2018;Bicycles&#x2019;, which are constrained bicyclic peptides that bind with high affinity and selectivity to their target. Bicycles combine the pharmacological properties characteristic of biologics with the manufacturing and pharmacokinetic advantages of small molecules. Bicycle&#xAE; is seeking to establish research collaborations to fully characterise these tools, and explore their potential application across different therapeutics areas with a disease area agnostic mind...

Bicycle Therapeutics is seeking proposals to enhance understanding of how their novel class of molecules interact with OX40 in cancer.

Bicycle® Toolbox: A Novel Chemical Modality to Explore the Role of OX40 Agonism in Disease

A major global personal care company is looking for novel antimicrobial molecules which are completely biodegradable, non-persistent and not aquatoxic, for use in cosmetic formulations. Our client is open to any novel molecules (e.g. small molecules, peptides and polymers), including molecules developed in other sectors (e.g. agrochemical, food or pharmaceutical) which may be applied to cosmetic and medical device applications. Molecules should target/disrupt bacterial membranes by any applicable modality e.g. cationic molecules with high charge density....

A major global personal care company is looking for completely biodegradable molecules with antimicrobial properties for use in cosmetic formulas.

Biodegradable Molecules with Antimicrobial Properties for use in Cosmetic Formulations

A worldwide manufacturing company is seeking alternative chemistries to liquid per- and polyfluoroalkyl substances (PFAS), specifically perfluoropolyether (PFPE), polyfluoroalkyl phosphate esters (PFAE) and fluorosilicones, which have raised environmental and health concerns due to their persistence, bioaccumulation, and potential toxicity. Ideally, these chemicals will be sustainable, cost-effective, and high-performance alternatives that can at least match the performance characteristics of PFAS-containing lubricants and research should comply with regulatory...

A worldwide manufacturing company is seeking alternative chemistries to liquid per- and polyfluoroalkyl substances.

Alternative Chemistries to Liquid PFAS

Procter &amp; Gamble, a world leading consumer goods company, is seeking synthetic biology expertise and approaches to produce platform chemicals, surfactants, chelants, polymers, perfume raw materials and enzymes. The Procter &amp; Gamble team is looking to explore solutions for sustainable, scalable production of chemicals (and their precursors) for use in the fabric, home care and beauty industries. The team has specific interests in sustainable synthesis of C1/C2 chemistry (platform chemicals) and long chain C12-14 and C16-18 chemistry, e.g. long chain fatty...

Procter & Gamble is seeking synthetic biology approaches for the sustainable production of chemicals (e.g. long chain fatty acids and oils, chelants and surfactants).

Synthetic Biology Approaches for Sustainable Production of Chemicals for the Fabric, Home Care and Beauty Industries

A pharmaceutical company focused on women&#x2019;s health is seeking novel druggable targets and drug candidates in the area of obstetrics and gynaecology for in-licence or early collaborative opportunities. The team is interested in new compounds and targets that will provide therapeutic benefit in the area of women&#x2019;s health, such as: infertility, polycystic ovary syndrome, diminished ovarian reserve, primary ovarian insufficiency, endometriosis, adenomyosis, uterine fibroid, menopause, senium, etc. <h3>Approaches of Interest:</h3> <ul> <li>All mechanisms of action relating ...</li></ul>

A pharmaceutical company focused on women’s health is seeking novel druggable targets and drug candidates in the area of obstetrics and gynaecology.

Engage with world leading R&D teams

Active campaigns

ico